Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

InMode reports Q3 revenue of $130.2M, revises guidance amid challenges

InMode faced challenges from macroeconomic headwinds, impacting international sales and necessitating a revision of full-year guidance.
Despite these challenges, the company demonstrated strong operational performance with high gross margins and strategic management changes.
Opportunities lie in new platform adoption, market realignment, and leveraging the strong cash position for future growth.
Overall, InMode remains well-positioned to navigate challenges and capitalize on opportunities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

There are two sides of the coin with this healthcare stock.

InMode Stock: Bull vs. Bear

Amazon

Bionano Genomics

Plug Power

Rivian Automotive

Shoals Technologies Group

Super Micro Computer

With the Nasdaq Composite having risen a robust 6% in the first two weeks of the New Year, it appears that the exchange, in line with my previous predictions, is well on its way to entering a bull market. Further, recent developments, including strong holiday-season retail sales growth and a month-over-month drop in December's Consumer Price Index, indicate that the Street's fears about the macro environment last year were tremendously overdone.

7 Must-Buy Nasdaq Stocks to Kick Off the First Quarter

Lovesac Company

Find out why the investment bank analysts who follow these stocks have such high hopes.

3 Top Growth Stocks That Could Shoot 39% to 95% Higher in 2023 According to Wall Street

InMode's growth is ramping up, and its valuation is on the cheap side, too.

Buy Shares of This Supercharged Growth Stock Today to Beat the Market in 2023

Doximity

Transmedics Group Inc

The stock market can't ignore forever how quickly these businesses are growing.

3 Explosive Growth Stocks to Buy Now That Could Rocket Higher in 2023

CRISPR Therapeutics

These two companies are in very different situations but could generate significant returns for investors.

More Likely to 5X First: CRISPR Therapeutics vs. InMode

Revenue in 2023 is expected to grow much slower than it has in recent years.

InMode Stock Dropped 9% Today

Intuitive Surgical

Intuitive Surgical disappointed Wednesday while InMode beat fourth-quarter views. But both ISRG stock and INMD stock fell in response.

Intuitive Surgical Dives As New System Rumors Flop; InMode Also Skids

Conference call to be held on Tuesday, February 14, 2023, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 11, 2023 /PRNewswire/ -- InMode Ltd.

InMode Expects Record Fourth Quarter & Full Year 2022 Financial Results, Q4 Revenue Between $133.2M-$133.4M

It seems the stock fell too much early in the year.

InMode Stock Actually Gained 59% in the Second Half of 2022. Is the Worst Over?

Medtronic

The medical equipment makers saw their share prices decline in 2022. Which one is more likely to stage a comeback in 2023?

Better Buy: InMode or Medtronic?

Inari Medical

UiPath

These companies are reporting financial results that aren't being reflected in their stock market performances.

3 Remarkable Growth Stocks That Could Climb 39% to 46%, According to Wall Street

Pubmatic

A bear market scorned for growth stocks is presenting some bargains for opportunistic investors.

3 Underappreciated Growth Stocks That Could Soar in 2023

Alphabet

2 Growth Stocks Wall Street Thinks Can Soar More Than 30%

YOKNEAM, Israel , Jan. 3, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chairman and Chief Executive Officer, Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present virtually at the 25th Annual Needham Growth Conference on Jan. 12, 2023.

InMode to Present at the 25th Annual Needham Growth Conference

After a long bear market, these innovative tech stocks are poised to shoot higher in 2023.

Nasdaq Bear Market: 3 Mind-Blowing Growth Stocks You'll Regret Not Buying on the Dip

Decelerating revenue is causing investors to wonder whether it can remain a leader in the large and growing market for cosmetic surgery alternatives.

Is InMode a Smart Stock to Buy in 2023?

Estee Lauder

MGM Resorts

Ferrari

XPeng

It's time to look for strong, potential breakout stocks. All as the outlook for the U.S. economy and the overall stock market start to improve.

7 Stocks on the Cusp of a Breakout

INMD provides a prime opportunity for investors to benefit from the growing demand for non-surgical cosmetic procedures that rely on energy-based devices. INMD manufactures and sells energy based devices used by physicians in these procedures and has between 2019 and 2022 seen an almost threefold jump in revenues.

Why InMode Deserves A Spot In Your 2023 Portfolio

DexCom

SoFi Technologies

Next year could be a very important one for all three of these fast-growing businesses.

3 Supercharged Growth Stocks to Buy for 2023

Duolingo

The folks who get paid to watch these stocks think they have growth potential that the rest of the market hasn't noticed yet.

3 Top Growth Stocks That Could Rise 44.1% to 58.9%, According to Wall Street

Outset Medical

These companies are disrupting the healthcare industry and growing rapidly.

2 No-Brainer Stocks to Buy Now That Could Soar in 2023

We were overly bearish on this excellent stock. Thereby, punishing us with a notable baked-in premium now, compared to June and September levels. INMD's excellent management team continues to prove the bears wrong, presenting stellar margins and profitability, despite the rising inflationary pressure and peak recessionary fears.

InMode: This Is Why We Were Wrong And Short-Sighted

Albemarle

BioNTech SE

Moderna

Sociedad Quimica Y Minera De Chile

Vista Oil & Gas SAB de CV

Vertex Pharmaceuticals

A stock that scores a perfect 10 should be on every investor's list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I'd considering a perfect 10.

7 Stocks on the Perfect 10 List

Sales aren't skyrocketing anymore, but InMode still has a solid business.

News for Inmode Ltd Stock (INMD)